Infinity Pharmaceuticals Inc. (INFI)

1.62
0.02 1.25
NASDAQ : Health Technology
Prev Close 1.60
Open 1.60
Day Low/High 1.56 / 1.62
52 Wk Low/High 1.00 / 2.92
Volume 189.54K
Avg Volume 107.80K
Exchange NASDAQ
Shares Outstanding 56.93M
Market Cap 90.51M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Commit To Buy Infinity Pharmaceuticals At $10, Earn 10% Using Options

Commit To Buy Infinity Pharmaceuticals At $10, Earn 10% Using Options

Investors eyeing a purchase of Infinity Pharmaceuticals Inc shares, but tentative about paying the going market price of $16.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $10 strike, which has a bid at the time of this writing of $1.00.

Infinity Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society Of Hematology Annual Meeting

Infinity Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society Of Hematology Annual Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated data from a Phase 1 monotherapy study of duvelisib (IPI-145), an inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which showed...

Infinity Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society Of Hematology Annual Meeting

Infinity Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society Of Hematology Annual Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today presented new preclinical translational data showing the complementary effects of inhibiting both PI3K-delta and PI3K-gamma, two enzymes known to play a role in...

Infinity Pharmaceuticals Stock Sees Short Interest Fall 18%

Infinity Pharmaceuticals Stock Sees Short Interest Fall 18%

The most recent short interest data has been released by the NASDAQ for the 11/14/2014 settlement date, which shows a 752,185 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 3,405,352, a decrease of 18.09% since 10/31/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock

Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Infinity To Present At The Deutsche Bank Securities 2014 BioFEST Conference

Infinity To Present At The Deutsche Bank Securities 2014 BioFEST Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Deutsche Bank Securities 2014 BioFEST Conference on December 1, 2014 at 2:15 p.

Infinity Pharmaceuticals (INFI) Is Strong On High Volume Today

Infinity Pharmaceuticals (INFI) Is Strong On High Volume Today

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold

Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold

Infinity Pharmaceuticals (INFI) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGRO, BGFV, BRKS, CHK, ELX, EML, INFI, INXN, JRJC, MRGE, POZN Downgrades: BDBD, CRESY, EXXI, HPTX, NUS, SANW, TSU Initiations: FTD, FUEL Read on to get TheStreet Quant Ratings' detailed report:

Infinity Reports Third Quarter 2014 Financial Results And Provides Company Update

Infinity Reports Third Quarter 2014 Financial Results And Provides Company Update

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported its third quarter 2014 financial results and updated its 2014 financial guidance based on the commencement of its global strategic collaboration with ...

Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented At ASH 2014 Annual Meeting

Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented At ASH 2014 Annual Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data for duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the American Society...

Infinity To Participate In Four Conferences In November

Infinity To Participate In Four Conferences In November

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following four upcoming conferences in November: Nomura Biotechnology Conference, Boston, November 6 th, panel at 12:15 p.

Infinity Announces The Date Of Its Third Quarter 2014 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Third Quarter 2014 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, November 6, 2014, at 4:30 p.

Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced encouraging topline data from its Phase 2a exploratory study of duvelisib (IPI-145), its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and ...

First Week Of INFI November 22nd Options Trading

First Week Of INFI November 22nd Options Trading

Investors in Infinity Pharmaceuticals Inc saw new options begin trading this week, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new November 22nd contracts and identified one put and one call contract of particular interest.

Why Infinity Pharmaceuticals (INFI) Stock Is Soaring Today

Why Infinity Pharmaceuticals (INFI) Stock Is Soaring Today

Shares of Infinity Pharmaceuticals (INFI) soared in morning trading Wednesday after the company partnered with Abbvie (ABBV) to develop and market Infinity's experimental blood cancer drug IPI-145, or duvelisib.

Infinity Pharma Snags Abbvie for Blood Cancer Drug Partnership

Infinity Pharma Snags Abbvie for Blood Cancer Drug Partnership

Infinity and Abbvie will jointly develop and market duvelisib.

Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology

Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc.

Infinity Enters Into Master Clinical Supply Agreement And Material Transfer Agreement With Roche

Infinity Enters Into Master Clinical Supply Agreement And Material Transfer Agreement With Roche

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has entered into a master clinical supply agreement with Roche under which Roche will supply Gazyva TM (obinutuzumab) to Infinity for use in planned...

Infinity Pharmaceuticals Stock Sees Short Interest Move 13% Lower

Infinity Pharmaceuticals Stock Sees Short Interest Move 13% Lower

The most recent short interest data has been released by the NASDAQ for the 08/15/2014 settlement date, which shows a 536,770 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 3,591,594, a decrease of 13.00% since 07/31/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Infinity To Participate In Two Conferences In September

Infinity To Participate In Two Conferences In September

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following upcoming conferences: FBR Inaugural Healthcare Conference, Boston, MA, September 3 rd (no presentation or...

Infinity Pharmaceuticals Stock Sees Short Interest Decrease By 11.6%

Infinity Pharmaceuticals Stock Sees Short Interest Decrease By 11.6%

The most recent short interest data has been released by the NASDAQ for the 07/31/2014 settlement date, which shows a 540,812 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 4,128,364, a decrease of 11.58% since 07/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Stocks Breaking Out With Unusual Volume

3 Stocks Breaking Out With Unusual Volume

These stocks rising on unusual volume are within range of triggering breakout trades.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Infinity Reports Second Quarter 2014 Financial Results And Provides Company Update

Infinity Reports Second Quarter 2014 Financial Results And Provides Company Update

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2014 financial results and ongoing progress with IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and ...

Infinity Amends PI3K-Delta, Gamma Agreement With Millennium

Infinity Amends PI3K-Delta, Gamma Agreement With Millennium

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that the company has purchased an option to buy out all future potential royalty payments due to Millennium: The Takeda Oncology Company for sales in ...

Interesting INFI Put And Call Options For August 16th

Interesting INFI Put And Call Options For August 16th

Investors in Infinity Pharmaceuticals Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For Infinity Pharmaceuticals

Relative Strength Alert For Infinity Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity Announces The Date Of Its Second Quarter 2014 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Second Quarter 2014 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, August 5, 2014, at 8:30 a.

Infinity To Participate In The BMO Capital Markets 3RD Annual Biotech Corporate Access Day

Infinity To Participate In The BMO Capital Markets 3RD Annual Biotech Corporate Access Day

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the BMO Capital Markets 3 rd Annual Biotech Corporate Access Day on July 29, 2014.

TheStreet Quant Rating: D (Sell)